A Multiple-dose, Subject- and Investigator-blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia
Latest Information Update: 07 Mar 2022
At a glance
- Drugs Canakinumab (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 28 Feb 2022 Primary endpoint (Change From Baseline of 4- Week Average Daily Pain Measured by Visual Analog Score (VAS) Over the Period of Week 8 to 12) has not been met according to the results published in the Blood
- 28 Feb 2022 Results published in the Blood
- 22 May 2020 This trial has been discontinued in UK (Global End Date: 27 Apr 2020), according to European Clinical Trials Database record.